Home|Journals|Articles by Year|Audio Abstracts
 

Case Report

Ann Med Res. 2013; 20(4): 364-366


Use of Rocuronium-Sugammadex in Patient who Prolonged Apnea Due to Pseudocholinesterase Deficiency During ECT

Vahap Sarıçiçek, Rauf Gül, Melda Doğan, Senem Koruk, Sıtkı Göksu

.




Abstract


Succinylcholine is widely used for muscle relaxation during Electroconvulsive therapy (ECT) mowing to its rapid onset and short duration of action. However, untoward side effects may occasionally occur, such as prolonged apnea associated with pseudocholinesterase deficiency. In cases where use of succinylcholine is inappropriate, muscle relaxants are needed to achieve a rapid onset of action and fast recovery equal to that is observed with succinylcholine. Sugammadex has a gamma-cyclodextrin structure, and binds to the rocuronium molecules in plasma and neuromuscular junction tightly in a one to one fashion and quickly inhibits the deep neuromuscular block. In this case report, we aimed to share our experience in the use of rocuronium-sugammadex during repeated sessions in a patient who experienced prolonged apnea associated with pseudocholinesterase deficiency during the first ECT. In conclusion, we believe that rocuronium and sugammadex may be used with confidence in cases requiring short procedures such as ECT.

Key Words: Electroconvulsive Therapy; Succinylch‾ Pseudocholinesterase Deficiency; Rocuronium; Sugammadex.






Full-text options


Share this Article


Online Article Submission
• ejmanager.com




ejPort - eJManager.com
Refer & Earn
JournalList
About BiblioMed
License Information
Terms & Conditions
Privacy Policy
Contact Us

The articles in Bibliomed are open access articles licensed under Creative Commons Attribution 4.0 International License (CC BY), which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.